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ARTICLE
Genetic Linkage to Chromosome 22q12 for a Heavy-Smoking
Quantitative Trait in Two Independent Samples
Scott F. Saccone, Michele L. Pergadia, Anu Loukola, Ulla Broms, Grant W. Montgomery,
Jen C. Wang, Arpana Agrawal, Danielle M. Dick, Andrew C. Heath, Alexandre A. Todorov,
Heidi Maunu, Kauko Heikkila¨, Katherine I. Morley, John P. Rice, Richard D. Todd, Jaakko Kaprio,
Leena Peltonen, Nicholas G. Martin, Alison M. Goate, and Pamela A. F. Madden
We conducted a genomewide linkage screen of a simple heavy-smoking quantitative trait, the maximum number of
cigarettes smoked in a 24-h period, using two independent samples: 289 Australian and 155 Finnish nuclear multiplex
families, all of which were of European ancestry and were targeted for DNA analysis by use of probands with a heavy-
smoking phenotype. We analyzed the trait, using a regression of identity-by-descent allele sharing on the sum and
difference of the trait values for relative pairs. Suggestive linkage was detected on chromosome 22 at 27–29 cM in each
sample, with a LOD score of 5.98 at 26.96 cM in the combined sample. After additional markers were used to localize
the signal, the LOD score was 5.21 at 25.46 cM. To assess the statistical signiﬁcance of the LOD score in the combined
sample, 1,000 simulated genomewide screens were conducted, resulting in an empirical P value of .006 for the LOD score
of 5.21. This linkage signal is driven mainly by the microsatellite marker D22S315 (22.59 cM), which had a single-point
LOD score of 5.41 in the combined sample and an empirical P value !.001 from 1,000 simulated genomewide screens.
This marker is located within an intron of the gene ADRBK2, encoding the beta-adrenergic receptor kinase 2. Finemapping
of this linkage region may reveal variants contributing to heaviness of smoking, which will lead to a better understanding
of the genetic mechanisms underlying nicotine dependence.
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Long-term cigarette smoking (susceptibility to tobacco ad-
diction [MIM 188890]) remains the leading behavioral risk
factor for early morbidity and mortality from disorders
such as lung cancer, heart disease, emphysema, and bron-
chitis in both men and women,1–3 in both industrialized
and developing countries,4 with risk for many of these
illnesses reported to increase sharply with the number of
cigarettes smoked.3,5,6 Whereas some have suggested that
research on the social causes of cigarette smoking should
be the priority,7 this argument is based largely on data
concerned with the initiation of smoking rather than on
outcomes in those who have become smokers. Although
the prevention of cigarette smoking among young people
is of undeniable importance, even complete success in
global elimination of all new onsets of cigarette smoking
would leave 4 million existing smokers per year to die
from smoking-related diseases.8
Very consistent evidence of genetic effects on long-term
persistence in smoking is found across sex, birth cohort,
and society in twin samples from Sweden, Finland, Aus-
tralia, and the United States. With controlling for factors
associated with risk for becoming a cigarette smoker, es-
timates of heritability for smoking persistence versus quit-
ting successfully have been found to be as high as 52%–
71%.9–14 Difﬁculty quitting cigarette smoking is believed
to be due to dependence on nicotine and perhaps other
components of tobacco. Substantial heritability15 has been
found for both DSM-based16 categorical and quantitative
measures of nicotine dependence, such as Fagerstro¨m-
based measures.17 Two important ﬁndings concerning the
heritability of nicotine dependence have been derived
through the multivariate genetic factor analysis of DSM-
and Fagerstro¨m-based symptom data obtained in a large
sample survey of adult Australian twins15: (1) a strong ge-
netic factor is, in large part, responsible for the clustering
of symptoms associated with nicotine dependence, and
(2) measures of the number of cigarettes smoked (includ-
ing a two-level variable derived fromMaxCigs24 [themax-
imum number of cigarettes smoked in a 24-h period], used
as an indicator of DSM-IV nicotine tolerance, and daily
smoking rate, used for Fagerstro¨m-based scales) are among
the items with the highest factor loadings in the genetic
analyses of these data (and, in women, are the highest).
This suggests that the degree of nicotine tolerance achieved
may be an important marker for genes contributing to risk
of nicotine dependence (most smokers achieve a level of
daily cigarette consumption that would have been toxic
when they ﬁrst started smoking).
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To our knowledge, there is only a small number of pub-
lished linkage studies that have targeted smoking persis-
tence or nicotine dependence, with ﬁndings mostly sug-
gestive and lacking replication. Using nicotine dependence
as a binary phenotype derived from the Fagerstro¨m Tol-
erance Questionnaire (FTQ)17 with the cutoff FTQ score
7, Straub and his colleagues18 found suggestive linkage
on chromosomes 2 and 10. More recently, Swan et al.19
found suggestive linkage on chromosome 6 for the Fager-
stro¨m Test for Nicotine Dependence (FTND)17 (LODp
) and a measure of nicotine withdrawal severity2.7
( ), on chromosome 7 for a quantitativemeasureLODp 2.7
of nicotine dependence ( ), on chromosome 8LODp 3.0
for a binary measure of DSM-IV nicotine dependence
( ), and on chromosome 16 for a pattern ofLODp 2.7
short-term quitting of cigarettes ( ). A recentLODp 4.0
study of African Americans found evidence of linkage for
several smoking phenotypes, including the FTND, to chro-
mosomes 9q31, 11p11, and 13q13.20 Another study found
linkage for the FTND in an African American sample on
chromosome 5 and in a European American sample on
chromosome 7.21 Suggestive linkage on nearly all the chro-
mosomes has been reported for measures of quantity of
cigarettes smoked, including measures of the average num-
ber of cigarettes smoked per day19 and the largest value
reported for this same measure in a longitudinal study
across baseline and series of follow-up assessments.22–27De-
spite the importance of nicotine tolerance to dependence
on nicotine, social restraints on times and places that cig-
arettes may be smoked may have reduced the informa-
tiveness of these daily consumption measures.28,29 A more
complicated phenotype has also been used, where two
dimensions of the smoking habit—numbers of cigarettes
smoked and number of years smoked—are combined in
the same measure.30–34 Overall, among the strongest sig-
nals from these ﬁndings is the multipoint LOD of 4.17 for
typcial quantity smoked on chromosome 10 at 92 cM.20
Additionally, there is overlap on chromosome 8 between
the studies of Ehlers et al.34 ( ) and Saccone etLODp 2.00
al.22 ( ) at ∼115 cM, on chromosome 9 betweenLODp 2.31
the studies of Li et al.24 ( ) at 101.64 cM and Gel-Pp .004
ernter et al.33 ( ) at 112.85 cM, and on chromo-Pp .001
some 11 between the studies of Li et al.24 (Pp 1.8#
) and Morley et al.27 ( ) at ∼65 cM. Additional510 Pp .004
linkage on chromosome 11 has been reported at 3 cM
( ).33Pp .0003
In the present study, we conducted a genetic linkage
analysis of a simple quantitative trait, MaxCigs24. This
trait represents a measure of tolerance to the effects of
nicotine, a key component of nicotine dependence.16 Al-
though the underlying genetic structure of MaxCigs24 is
unlikely to be identical to that of nicotine dependence, it
is expected to share common genetic risk factors15 and has
the advantage of grading both dependent and nondepen-
dent individuals. Whereas recent restrictions on the times
and locations where smoking is allowed have had a neg-
ative impact on the informativeness of reports of typical
daily cigarette consumption, it is reasonable to expect that
MaxCigs24 would be more robust than typical measures
of cigarette use to such kinds of limitations.
As part of an international consortium known as “the
Nicotine Addiction Genetics (NAG) project,” investigators
from Australia, Finland, and the United States are using
population-based samples to identify genes harboring risk
loci for heavy cigarette smoking and nicotine dependence
and to understand the relative importance of these genes
in determining risk of becoming a long-term, dependent
cigarette smoker. Toward this goal, we conducted genome
scans using DNA from 1450 Australian and Finnish fam-
ilies. Presented here are ﬁndings for a measure of nicotine
tolerance that, as prior research suggests,15 may be a strong
behavioral marker for genes associated with nicotine de-
pendence and is a phenotype for which we ﬁnd replicated
evidence of linkage.
Subjects and Methods
Family Ascertainment
The study participants for the NAG project were enrolled at
two different sites: the Queensland Institute of Medical Research
(QIMR) in Australia and the University of Helsinki (UH) in Fin-
land (see table 1). Families were identiﬁed through heavy-smok-
ing index cases by use of previously administered interview and
questionnaire surveys of the community-based Australian and
population-based Finnish registers of twins. The Finnish arm of
the NAG project recruited families from the Finnish TwinCohort,
which consists of all Finnish twin pairs born between 1938 and
1957. Families chosen for the Australian arm of the NAG study
were identiﬁed from two cohorts of the Australian Twin Panel,
which included spouses of the older of these two cohorts, for a
total of ∼12,500 families with information about smoking. The
ancestry of the Australian samples is predominantly Anglo-Celtic
or northern European (190%).
We also used data obtained from a third Australian community-
based family study, the Australian Big Sibship Study (BigSib), for
the purpose of obtaining population estimates of our quantitative
trait. The BigSib sample comprises families ascertained through
the Australian Twin Panel selected for ﬁve or more offspring shar-
ing both biological parents (see table 1). This is a reasonable ap-
proach, since we have found sibship size to be uncorrelated with
cigarette smoking outcomes in ever-smokers (those who have at
least tried cigarettes, even a puff). The BigSib sample includes
1,254 families that were unselected with respect to alcohol use,
tobacco use, or any other form of psychopathology. Families for
the BigSib sample were recruited from the same Australian Twin
Panel sources as were the NAG Australian families, and pheno-
typic information was obtained using the same assessment pro-
tocol as for the NAG.
All data-collection procedures were approved by institutional
review boards at Washington University (WU), the QIMR, and
the UH, including the use of appropriate and approved informed-
consent procedures. Participants gave informed consent for an
interview, for providing a blood sample for DNA extraction and
cell lines, and for the sharing of their anonymous clinical and
genotypic records and DNA with other scientists outside of this
project’s research team of investigators. If the subject was an
index case, permission was requested to contact other family
members.
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Table 1. Summary Statistics for the Three Samples
Characteristic
Summary Statistics by Sample
Australian
NAGa
Finnish
NAGa
Australian
BigSibb
No. of families: 289 154 1,254
Offspring, meanSD 3.2 1.4 3.2 1.4 4.1 1.8
No. (%) of men 590 (45.0) 260 (50.8) 2,389 (44.3)
No. (%) of women 721 (55.0) 252 (49.2) 3,003 (55.7)
Total no. of subjects 1,311 512 5,392
Age range (years) 21–86 29–91 18–91
Age, meanSD (years) 48.8 14.1 57.9 7.3 46.1 10.7
No. (%) of subjects considered heavy smokers:
Men 449 (76.1) 122 (47.5) 862 (38.4)
Women 389 (57.8) 110 (46.6) 720 (27.3)
No. (%) of subjects who meet DSM-IV criteria for nicotine dependencec:
Men 402 (75.1) 117 (47.5) 824 (56.3)
Women 398 (71.4) 95 (47.3) 903 (56.8)
No. of subjects who meet FTND12 criteria for nicotine dependencec (cigarette ranged):
Men: 535 (0–10) 246 (0–10) 1,463 (0–10)
MeanSD no. of cigarettes 4.8 2.5 3.8 2.2 3.4 2.7
Women: 557 (0–10) 201 (0–10) 1,589 (0–10)
MeanSD no. of cigarettes 4.0 2.6 3.2 2.5 2.8 2.6
No. of subjects who meet MaxCigs24 criteria (cigarette ranged):
Men: 537 (3–98) 247 (2–98) 1,462 (1–98)
MeanSD no. of cigarettes 44.3 19.7 34.8 16.7 35.0 19.5
Women: 561 (2–98) 202 (2–60) 1,597 (2–98)
MeanSD no. of cigarettes 33.1 16.1 22.4 10.8 26.7 14.9
NOTE.—All families are nuclear.
a The ﬁgures reported are for genotyped individuals.
b A community-based Australian sample that was used to determine population estimates of parameters related to our quantitative trait; we
report only on those subjects who were interviewed.
c Regular smokers only (at least 100 cigarettes, lifetime).
d Cigarette range indicates no. of cigarettes, lifetime. Values of 99 or greater were rounded to 98.
Clinical Assessment
The data-collection protocol included two phases—a telephone
screening and a diagnostic interview phase—after which a sample
of blood for DNA extraction was requested. Eligible families from
both sites were required to have at least one adult sib pair (not
including MZ twin pairs) concordant for a history of cigarette
smoking, determined by earlier questionnaire or interview sur-
veys. At the Australian site, families were targeted for screening
with use of the criterion that they have at least one sib pair
concordant for a lifetime history of heavy smoking (deﬁned as
either a history of smoking 20 cigarettes per day during the period
of heaviest smoking or smoking at least 40 cigarettes in any 24-
h period). Priority was given to families with available biological
parents. Unless both parents were available, an attempt wasmade
to obtain clinical data and a blood specimen from at least one
unaffected full biological sibling. At the Finnish site, because of
the absence of information on cigarette-smoking history in other
nontwin siblings, families with DZ cotwins concordant for a life-
time history of regular smoking were screened and enrolled in
the study. Priority was given to families of DZ twins with histories
of heavier cigarette consumption. At both sites, during the screen-
ing interview, sufﬁcient information on a lifetime history of cig-
arette smoking was obtained from the index case, to conﬁrm
family eligibility, and permission was requested to contact avail-
able parents and full biological siblings for participation in the
study.
Clinical data were collected using a computer-assisted tele-
phone diagnostic interview (CATI), an adaptation of the Semi-
Structured Assessment for the Genetics of Alcoholism (SSAGA)35,36
for telephone administration. The tobacco section of the CATI
was derived from the Composite International Diagnostic Inter-
view (CIDI)37 and incorporated standard FTND, DSM-IIIR, and
DSM-IV assessments of nicotine dependence. It also included a
detailed history of the ﬁrst use of cigarettes and other tobacco
products; the quantity and frequency of use for current, most
recent, and heaviest period of use; and supplemental items con-
cerning attempts at cessation. Information on other comorbid
psychiatric disorders, such as major depression and anxiety dis-
orders, and conduct and antisocial personality disorders (with use
of DSM-IIIR and DSM–IV criteria) was elicited by the CATI. The
mailed questionnaire survey included personality scales (NEO38)
and obtained additional information on cigarette use and nico-
tine dependence (the Nicotine Dependence Syndrome Scale39).
Interviewers were selected from trained panels of interviewers at
QIMR and the UH, which include nurses or graduates in Psychol-
ogy or a related ﬁeld.
At the Australian site, a diagnostic telephone interview was
completed by 3,425 Australians (1,800 women), and 2,912 blood
samples were obtained (including 1,557 from women and in-
cluding 807 from parents) from these individuals. DNA from 953
Australian individuals in 289 families and from 623 Finnish in-
dividuals in 155 families who were identiﬁed as informative for
the heaviness-of-smoking phenotype was sent for a genome scan.
DNA was available from an additional 133 who refused to give
blood but provided a buccal sample. At the Finnish site, a diag-
nostic telephone interview was completed by 2,265 Finnish sub-
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jects (1,058 women), and 2,224 samples of blood were collected
(1,057 from female subjects and 171 from subject parents).
If it was determined during the interview that the subject was
a regular smoker (smoked100 cigarettes, lifetime; 10 additional
Australian genotyped individuals and 1 Finnish genotyped in-
dividual were also considered to be regular smokers, since they
smoked 26–99 cigarettes, lifetime, and smoked weekly for 2
mo), the subject was then asked “What is the largest number of
cigarettes you have ever smoked in a 24-h period?” (MaxCigs24).
If a subject reported that he or she had smoked 198 cigarettes in
a 24-h period, then MaxCigs24 was coded 98. MaxCigs24 is a
quantitative phenotype that has acceptable long-term test-retest
reliability and high heritability in both men and women. Using
a volunteer cohort of adult Australian twins,15 some of whom
were included in the linkage analyses, we computed the extent
to which individual differences in the liability to MaxCigs24 in
regular smokers was due to heritable and environmental inﬂu-
ences, and we estimated the heritability to be 55% (95% CI 48%–
60%). The 5-year test-retest reliability observed in Australian
twins is 0.72. The correlation of MaxCigs24 with measures of
nicotine dependence is substantial. In the BigSib sample, among
regular smokers, both men and women, the correlation of Max-
Cigs24 with FTND is 0.67, and the correlation with the DSM-IV
symptom count is 0.64.
Table 1 shows the distributions of smoking outcomes for the
Australian NAG, Finnish NAG, and BigSib samples. For the off-
spring generation (not shown), the approximate mean age (SD)
at onset of weekly smoking (smoked at least once per wk for at
least 2 mo) is in the Australian NAG sample,16.1 3.5 18.2
in the Finnish NAG sample (an older sample), and4.7 17.4
in the BigSib sample. The number of years smoked is4.1
∼ in the Australian NAG sample, in the19.0 8.8 28.8 12.7
Finnish NAG sample, and in the BigSib sample.18.0 10.8
Genotyping and Cleaning
The genome screen for the Australian NAG sample was based on
a set of 381 autosomal microsatellite markers spaced at ∼10 cM
throughout the autosomal genome. At the time of analysis, geno-
type data for the Finnish NAG sample were available for a subset
of 362 of these markers. The excluded markers were distributed
randomly throughout the genome, and these exclusions did not
affect the overall mean spacing in the Finnish marker set. The
genetic map used for our analysis is based on the deCODE genetic
map.40 A few of the markers used in our study were not part of
the deCODE set and were assigned genetic map positions on the
basis of an interpolation of the physical map obtained from build
36.2 of the human reference genome (National Center for Bio-
technology Information [NCBI]). The AustralianNAG samplewas
genotyped at the Australian Genome Research Facility (AGRF),
and the Finnish NAG sample was genotyped at the Finnish Ge-
nome Center (FGC). The AGRF used an ABI (Applied Biosystems)
genotyping platform, and the FGC used both ABI andMegaBACE
(Amersham Biosciences) platforms. To reﬁne the linkage signal
found on chromosome 22, two additional microsatellite markers
ﬂanking D22S315—namely, D22S1174 and D22S1144—were ge-
notyped for the Finnish NAG sample at the FGC and for the
Australian NAG sample at WU, with use of an ABI 3100 platform.
Low-level processing and database management for the geno-
type data were performed using the statistical/database package
SAS and the Perl programming language. The genotype data were
then screened forMendelian errors and familialmisspeciﬁcations,
such as cases of nonpaternity, with the computer programs Ped-
Check (v. 1.1),41 RelCheck (v. 0.67),42,43 and PREST (v. 3.0).44 After
measures were taken to correct for familial misspeciﬁcations, any
genotypes producingMendelian errors were deleted, and the error
rate was computed as the percentage of nonmissing alleles that
were removed. We then tested the markers for Hardy-Weinberg
equilibrium (HWE), using a x2 statistic as implemented in the
program PedStats (v. 0.4.6).45 One marker, D21S1256, had a sig-
niﬁcance level of in the HWE test and an error rate ofP ! .0001
38% (the median rate was 0.3%) and was dropped from the
analysis.
Determination of the Trait in the Australian Sample
To minimize the effects of ascertainment in the genotyped Aus-
tralian NAG sample, we used the community-based BigSib sample
to determine how to correct for skewness, adjust for outliers, and
correct for covariates in the genetic analysis of MaxCigs24. The
distribution of MaxCigs24 in both the BigSib and AustralianNAG
samples is shown in ﬁgure 1A.
We now describe how the trait was determined in the BigSib
sample. To reduce skewness in the distribution of MaxCigs24, we
considered the transformations , , and . Thelog (x) log (x 1) x
square-root transformation was clearly the most effective. It re-
duced the skewness from 0.97 to 0.03 and the kurtosis from 1.60
to 0.08. We then corrected the square root of MaxCigs24 for co-
variates with a linear regression by use of SAS. To determine the
best model, the F statistic was used to measure the overall ﬁt by
testing the null hypothesis that all coefﬁcients in the linear re-
gression except the intercept are 0, and a t test was used to test
the signiﬁcance of individual terms in the linear regression by
testing the null hypothesis that the coefﬁcient of the term is 0.
Each of these tests was implemented in SAS with use of the REG
procedure. The covariates considered were sex, age, ,sex# age
and age2. Although and age2 were both signiﬁcant co-sex# age
variates, the sex and age model gave the best ﬁt. After the re-
gression was performed, the distribution of the residual was
examined to identify outliers. The original values of MaxCigs24
corresponding to residuals 13 SDs from the mean were rounded
down to 80/d for the upper end of the distribution and rounded
up to 5/d for the lower end of the distribution. The linear re-
gression was repeated to achieve a better ﬁt, and the ﬁnal trait,
which we denote as “CMaxCigs24,” was deﬁned as the residual
between the measurement and its predicted value.
To determine CMaxCigs24 in the Australian NAG sample, we
applied the same rule to adjust MaxCigs24 for outliers, took the
square root, and used the coefﬁcients from the linear regression
determined by the BigSib sample to compute the residual in the
NAG sample. The distribution of CMaxCigs24 in the BigSib and
NAG samples is plotted in ﬁgure 2.
Determination of the Trait in the Finnish Sample
Since we did not have access to a community-based Finnish sam-
ple and since population estimates of mean and variance of Max-
Cigs24 in the Finnish population (see ﬁg. 1B for the distribution)
were not available, the determination of the quantitative trait in
the Finnish NAG sample was based solely on the sample itself
(i.e., 2,265 Finnish diagnostic telephone interviews). Otherwise,
the methodology was analogous to that of the Australian sample.
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Figure 1. Distribution of the MaxCigs24 in the Australian BigSib (top) ( ) and NAG (middle) ( ) samples and inNp 3,059 Np 1,098
the Finnish NAG sample (bottom) ( ). After 60 cigarettes, the bars represents bins of 5 cigarettes (e.g., the bar labeled “100”Np 449
is for MaxCigs 195).
Determination of the Trait in the Combined Australian
and Finnish Sample
We deﬁned the quantitative trait in the combined Australian and
Finnish NAG sample by converting CMaxCigs to Z scores in each
sample individually and by analyzing the combined sample using
a mean of 0 and a variance of 1. The estimates of mean and
variance in the AustralianNAG sample were taken from the BigSib
sample.
Linkage Analysis
We tested CMaxCigs24 for genetic linkage with a method intro-
duced by Sham et al.,46 which is a derivative of the classic re-
gression-based technique of Haseman and Elston.47Weperformed
a linear regression of the number of alleles identical by descent
(IBD) for a relative pair on the square of the sum and the square
of the difference of the trait values. This method is implemented
by the computer program Merlin-Regress,46 a component of the
Merlin (v. 0.10.2) software suite,48 and computes both single-
point and multipoint LOD scores. Estimates of IBD were com-
puted internally by the program Merlin-Regress. To assess the
amount of genetic information provided by the data, we com-
puted an entropy-based measure as implemented by the program
Merlin, which provides this measure on amultipoint basis so that
it can be plotted simultaneously with the LOD scores.
This regression method allows for the speciﬁcation of three
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Figure 2. Distribution of the CMaxCigs24 trait in the Australian NAG and BigSib samples. CMaxCigs24 is the quantitative trait used
for genetic linkage analysis. Shown is the distribution in the community-based Australian BigSib sample and the ascertained (and
genotyped) Australian NAG sample. Also shown is the normal curve, with mean and variance estimated from the BigSib sample. As
should be expected, the distribution in the ascertained sample is shifted to the right.
Figure 3. Maximum multipoint LOD scores for each chromosome
from the genomewide linkage screen of CMaxCigs24.
parameters of the quantitative trait: mean, variance, and heri-
tability. In light of our own estimates of heritability (see the “Clin-
ical Assessment” section), we used the default heritability of 50%
in Merlin-Regress. For the analysis of the Australian NAG sample,
we used the estimates of mean and variance from the Australian
BigSib sample; for the Finnish NAG sample, we used the estimates
from the sample itself.
In the combined Australian and Finnish NAG sample, allele
assignments and frequencies were calculated separately for each
of the genotyped samples and therefore sum to 2 rather than 1.
Normally, Merlin-Regress forces allele frequencies to sum to 1.
We therefore made a slight modiﬁcation to the program’s source
code to circumvent this issue (G. Abecasis, personal communi-
cation). Because of the large number of alleles observed, it was
also necessary to compile the program with the special 64-bit
integer option USE_LONG_INT.
Simulations and Empirical P Values
Deviations from normality, such as skewness and outliers, are a
concern when the regression method described in the “Linkage
Analysis” section is used, and it is prudent to perform simulations
to determine empirical P values.46 Merlin48 was used to generate
simulated genotype data that preserve the original family struc-
ture, phenotypes, and allele frequencies. To run simulations on
the combined sample, it was necessary to ﬁrst generate simu-
lated data sets for the Australian and Finnish samples individu-
ally. Once the simulated data were generated for each of the two
samples, the two simulated data sets were combined using the
method described in the “Linkage Analysis” section. We gener-
ated 1,000 simulated samples of combinedAustralian andFinnish
genotype data. The samples were each tested for linkage with use
of the same regression method implemented by Merlin-Regress,
with use of the same trait and trait parameters as for the analysis
of the real genotype data. The empirical P value for a LOD scoreˆp
L was calculated by counting the number of times, r, the LOD
score exceeded L in the simulated data and by applying the for-
mula .49,50ˆpp (r 1)/1,001
Results
The maximum multipoint LOD score in the Australian
NAG sample was 3.05 on chromosome 22 at 26.96 cM
(table 2 and ﬁg. 3). No other chromosome showed a peak
LOD score 12 for this phenotype in the Australian sample.
In the Finnish NAG sample, the maximum multipoint
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Table 2. Multipoint Linkage Results from the Analysis of CMaxCigs24
Chromosome,
and Positiona (cM) Flanking Marker(s)
LOD Score by Sample
Australian Finnish Combined
Original genomewide screen:
1:
48.00 D1S234 and D1S255 .99 .16 1.08
68.00 D1S255 and D1S2797 1.49 .40 1.84
3:
102.89 D3S1566 and D3S3681 .01 1.87 .37
5:
125.19 D5S471 and D5S2115 1.25 .03 .62
7:
115.51 D7S515 and D7S486 1.27 .07 1.08
145.51 D7S640 and D7S684 1.53 .70 2.23
12:
32.00 D12S364 and D12S310 1.05 .46 1.51
46.00 D12S1617 and D12S345 .00 1.79 .63
74.00 D12S5368 and D12S83 1.23 .20 1.32
13:
123.85 D13S285 1.16 .36 .32
17:
30.63 D17S1852 and D17S799 .01 1.39 .62
20:
44.90 D20S112 and D20S195 .81 1.53 2.08
72.90 D20S119 and D20S178 .49 4.22 2.82
22:
26.96 D22S315 and D22S280 3.05 3.16 5.98
44.96 D22S283 and D22S423 1.79 .36 2.05
After localization of linkage peak
on chromosome 22:
22:
25.46 D22S315 and D22S1144 2.48 3.03 5.21b
NOTE.—LOD scores 13 are shown in bold.
a Chromosomal locations where the LOD score of a multipoint linkage peak was 11 in at least
one of the three samples: Australian, Finnish, and combined. The chromosomal positions are de-
termined by the largest of the three LOD scores and are based on the deCODE genetic map.32 For
example, the table shows the result on chromosome 22 at 26.96 cM, because this is the location
of the peak in the combined sample, whereas the Finnish sample actually peaks at 28.96 cM, with
a LOD of 3.23.
b Empirical P value of .006 from 1,000 genomewide multipoint linkage simulations.
LOD score for MaxCigs24 was 4.22 on chromosome 20 at
72.90 cM. There was also a LOD score of 3.23 on chromo-
some 22 at 28.96 cM and a LOD score of 1.78 on chromo-
some 12 at 46.00 cM. In the combined sample, the max-
imum LOD score was 5.98 on chromosome 22 at 26.96
cM. There was another peak on chromosome 22 with a
LOD score of 2.05 at 44.96 cM, and the LOD score for the
peak on chromosome 20 at 72.90 cM from the Finnish
sample dropped to 2.82 in the combined sample. The link-
age peak on chromosome 22 at 26.96 cM appears to be
driven mainly by marker D22S315 (22.59 cM), which had
a single-point LOD score of 5.41 in the combined sample.
Additional Genotyping
Because the linkage peak on chromosome 22 lies between
markers D22S315 and D22S280, which are separated by a
gap of 17 cM, two additional markers ﬂankingD22S315—
namely, D22S1174 and D22S1144—were genotyped in an
effort to localize the linkage signal. The resulting linkage
peak in the combined sample shifted toward D22S315
(22.59 cM), from a LOD score of 5.98 at 26.96 cM to a
LOD score of 5.21 at 25.46 cM (ﬁg. 4). The multipoint
LOD score in the Australian sample peaked at 23.96 cM,
with a LOD score of 2.54, and, for the Finnish sample, the
peak was at 26.46 cM, with a LOD score of 3.09.
Simulations
We analyzed 1,000 simulated combined Australian and
Finnish samples for MaxCigs24, using genotype data that
included both the original screening set of 381 markers
and the two additional markers on chromosome 22. There
were ﬁve multipoint LOD scores from the simulated data
15.21, which ranged from 5.28 to 6.53. Hence, the em-
pirical P value for the multipoint LOD score of 5.21 found
on chromosome 22 in the real data is .006. There were no
single-point LOD scores from simulated data 15.41, which
implies that the empirical P value for the single-point LOD
score of 5.41 at marker D22S315 in the real data is !.001.
Discussion
We tested MaxCigs24 for genetic linkage, using a genome-
wide approach in two independent samples. The most
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Figure 4. The linkage peak on chromosome 22. Shown are the multipoint LOD scores for CMaxCigs24 after two markers (shown in
boldface) ﬂanking D22S315 were added to the original genomewide screening set.
compelling evidence of linkage was on chromosome 22
at 27–29 cM, where the multipoint LOD scores in the
Australian and Finnish samples were 3.05 at 26.96 cM and
3.23 at 28.96 cM, respectively (table 2 and ﬁg. 3). This
overlap is particularly noteworthy, given that, whereas co-
ordinated across sites, the data collection, genotyping, and
cleaning occurred at different sites for each sample. The
combined Australian and Finnish sample produced amul-
tipoint LOD score of 5.98 at 26.96 cM that appears to be
driven mainly by marker D22S315 (22.59 cM), which had
a single-point LOD score of 5.41. Because the multipoint
linkage peak occurred between two microsatellite markers
that are separated by a wide gap of 17 cM, the location
of the peak is uncertain. To address this issue, we ge-
notyped two additional microsatellite markers in both
the Australian and Finnish samples, one on each side of
D22S315. The result of this additional information was
that the location of the linkage peak on chromosome 22
in the combined sample shifted to a LOD score of 5.21 at
25.46 cM, which is closer to D22S315 (ﬁg. 4). The empir-
ical P value of this LOD score from 1,000 genomewide
multipoint simulations score is .006, and the empirical P
value for the single-point LOD score of 5.41 is !.001.
Hence, it is unlikely that these signals are due to random
effects. We also see elevated single-point LOD scores for
typical daily cigarette consumption (Finland only: LOD
2.59; data not shown) and for the FTND measure of nic-
otine dependence (combined sample: LOD 2.20; data not
shown) at this location.
Two previous studies that examined other measures of
tobacco use22,34 and two studies of alcohol dependence
(MIM 103780)51,52 (a commonly associated phenotype)
found small signals on chromosome 22, with one more
proximal to our ﬁnding.51 It may be the case that reﬁne-
ment of the tobacco-use phenotype in addition to target-
ing heavy-smoking samples, as exempliﬁed here, helped
to hone this area of potential genetic risk for nicotine
tolerance.
Previous analyses of Australian twin data suggest that a
strong genetic factor underlies the clustering of symptoms
associated with nicotine dependence and that the number
of cigarettes consumed, or measures of nicotine tolerance,
may be an important marker for genes contributing to risk
of nicotine dependence in at least some smokers.15 There
is no critical value in the distribution of MaxCigs24 that
distinguishes those with nicotine dependence. However,
the correlation of MaxCigs24 with other nicotine-depen-
dence phenotypes was found to be substantial in a large
community sample of Australian families (the BigSib sam-
ple). Among regular smokers (those with a history of smok-
ing 100 cigarettes) with a lifetime history of smoking
!20 cigarettes in any 24-h period, !3% of male and 6% of
female smokers reported a lifetime history of DSM-IV nic-
otine dependence. Among those with a history of smoking
140 cigarettes in any 24-h period, 186% of male and 92%
of female cigarette smokers reported a lifetime history of
dependence. Whereas dichotomous phenotypes are clin-
ically important, MaxCigs24 has the advantage of quan-
titatively grading the severity of cigarette use and making
use of the full range of individual differences in cigarette
use and nicotine tolerance among regular smokers. In ad-
dition, the number of cigarettes smoked in any 24-h pe-
riod may be less affected by the increasing number of
restraints on the times and places where cigarette smoking
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is permitted, such as smoking restrictions in restaurants
and workplaces, which may reduce the informativeness
of reports of typical daily cigarette consumption, a mea-
sure that has been used in other linkage studies of smoking
behavior.
At the time of analysis, the Finnish NAG sample was
genotyped for a subset of 362 markers from the full 10-
cM screening set used for the Australian NAG sample. The
omitted markers were distributed randomly throughout
the genome, which resulted in an occasional gap in cov-
erage. Large gaps between markers are a concern, because
they can artiﬁcially inﬂate LOD scores and lead to false-
positive results. The only LOD score 11 in the Finnish
sample that was near a gap in the Finnishmarker coverage
was on chromosome 20 at 72.90 cM, where the LOD score
was 4.22 (table 2). The closest markers to this peak that
were genotyped for the Finnish sample were D20S119
(69.40 cM) and D20S100 (88.96 cM). However, the peak
is very close to marker D20S119, so inﬂation of this LOD
score is not as much of a concern as it would be if the
peak were located near the midpoint of the ﬂankingmark-
ers. Additional markers should be genotyped to localize
this linkage signal. In the simulated linkage analyses, in-
ﬂation of the LOD scores would make the empirical P
values larger and, if anything, cause us to underestimate
the signiﬁcance of our results.
The genotypedAustralian and FinnishNAG sampleswere
ascertained through an affected sibling pair concordant
for smoking history. This ascertainment scheme may in-
ﬂuence the results of our quantitative linkage analysis.We
controlled for the effects of ascertainment in the Austra-
lian sample with the BigSib sample, a large collection of
Australian families chosen simply for large sibship size,
which was used to make estimates of the mean and var-
iance of the distribution of MaxCigs24. Since no com-
munity-based Finnish sample was available, the corre-
sponding estimates of these parameters for the Finnish
analysis were sample based. It was shown by Sham et al.46
that the misspeciﬁcation of mean and variance will only
weaken the power to detect linkage and will not inﬂate
the type I error rate. The only case of model misspeciﬁ-
cation that Sham et al.46 found that inﬂated the type I
error rate was when the heritability was severely under-
estimated and a diallelic marker with equal allele frequen-
cies was used; even in this case, the inﬂation was very
slight. Hence, our ﬁnding of linkage to chromosome 22
in the Finnish sample, which supports the evidence in the
Australian sample at the same locus, is particularly im-
pressive, given that the phenotype may suffer from power
loss due to model misspeciﬁcation.
By its very nature, linkage analysis is a tool that deals
with a low genomic resolution, and positive results may
implicate many genes. If we consider the reﬁned peak on
chromosome 22 after additional markers were genotyped
(ﬁg. 4), the 1-LOD support is the 9.50-cM interval from
20.96 cM to 29.46 cM. This corresponds to the physical
region extending from23.843Mb to 26.020Mb, according
to build 36.2 of the human reference genome (NCBI), a
2.2-Mb region containing ∼25 genes. However, the linkage
signal is driven mainly by marker D22S315 (22.59 cM)
(UniSTS), which lies in an intron of the geneADRBK2 (MIM
109636), encoding the beta-adrenergic receptor kinase 2.
The ADRBK2 gene product is involved in the desensiti-
zation of multiple G-protein receptor systems, such as do-
pamine and corticotrophin releasing factor,53,54 and is an
interesting candidate protein for moderating loci for nic-
otine dependence via regulating the reinforcing effects of
catecholamines. In addition, anADRBK2-knockoutmouse
has been shown to alter opiate tolerance55 (although there
has been no examination of effects on tolerance to nic-
otine, to our knowledge).
We also found signiﬁcant evidence of linkage to chro-
mosome 20 in the Finnish sample, where the peak mul-
tipoint LOD score was 4.22 at 72.90 cM (table 2) (2-LOD
support 64–86 cM). It is noteworthy that the a4 nicotinic
receptor gene, CHRNA4 (MIM 118504), is positioned at
∼98 cM on chromosome 20 (EntrezGene), although the
evidence of linkage to this gene from our analysis is weak.
The 2004 Surgeon General’s report highlights the fact
that cigarette smoking continues to be the single most
preventable cause of death in the United States, its impact
pervading all strata of sex, age, culture, and demography.56
The moderate-to-high heritability of both nicotine depen-
dence and heavy smoking indicates that disentangling the
sources of genetic risk associated with smoking may pro-
vide substantial biological insight into this disorder. To
our knowledge, this is the ﬁrst article to report consistent
evidence of genetic linkage with use of the same quanti-
tative smoking phenotype assessed identically in two in-
dependent samples. Whereas the linkage region we iden-
tiﬁed encompasses many genes, the evidence appears to
be strongest at ADRBK2, a plausible candidate gene for the
study of nicotine dependence. Finemapping of this region
may reveal genetic variants contributing to cigarette smok-
ing and ultimately aid our comprehension of the complex
etiologic pathways involved in nicotine dependence.
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